Suicidal ideation and behavior associated with antidepressant medications: Implications for the treatment of chronic pain

Pain

Volumn 155, Issue 12, 2014, Pages 2471-2475

  Pereira, Anthony ^a   Conwell, Yeates ^a   Gitlin, Michael J ^b   Dworkin, Robert H ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; FLUOXETINE; PAROXETINE; PLACEBO; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ANALGESIA; AUTOMUTILATION; CHRONIC PAIN; COHORT ANALYSIS; DRUG INDICATION; DRUG SAFETY; HUMAN; META ANALYSIS (TOPIC); PRIORITY JOURNAL; PROPENSITY SCORE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SUICIDAL BEHAVIOR; SUICIDAL IDEATION; SUICIDE ATTEMPT; SYSTEMATIC REVIEW; VETERAN; BIBLIOGRAPHIC DATABASE; COMPLICATION; DEPRESSION; PSYCHOLOGY; STATISTICS AND NUMERICAL DATA;

ANTIDEPRESSIVE AGENTS; CHRONIC PAIN; DATABASES, BIBLIOGRAPHIC; DEPRESSION; HUMANS; SUICIDAL IDEATION; SUICIDE, ATTEMPTED;

EID: 84922692623     PISSN: 03043959     EISSN: 18726623     Source Type: Journal    
DOI: 10.1016/j.pain.2014.08.022     Document Type: Review

References (40)

1. Attal N, Cruccu G, Baron R, Haanpää M, Hansson P, Jensen TS, Nurmikko T. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 Revision. Eur J Neurol 2010;17:1113-23.
2. Bair MJ, Robinson RL, Katon W, Kroenke K. Depression and pain comorbidity: a literature review. Arch Intern Med 2003;163:2433-45.
3. Calandre EP, Navajas-Rojas MA, Ballesteros J, Garcia-Carrillo J, Garcia-Leiva JM, Rico-Villademoros F. Suicidal ideation in patients with fibromyalgia: a cross-sectional study. Pain Pract 2014. http://dx.doi.org/10.1111/paper.12164.
4. Carpenter DJ, Fong R, Kraus JE, Davies JT, Moore C, Thase ME. Meta-analysis of efficacy and treatment-emergent suicidality in adults by psychiatric indication and age subgroup following initiation of paroxetine therapy: a complete set of randomized placebo-controlled trials. J Clin Psychiatry 2011;72:1503-14.
5. Carville SF, Arendt-Nielsen S, Bliddal H, Blotman F, Branco JC, Buskila D, Da Silva JA, Danneskiold-Samsoe B, Dincer F, Henriksson C, Henriksson KG, Kosek E, Longley K, McCarthy GM, Perrot S, Puszczewicz M, Sarzi-Puttini P, Silman A, Spath M, Choy EH. EULAR evidence-based recommendations for the management of fibromyalgia syndrome. Ann Rheum Dis 2008;67:536-41.
6. ® 2007;132:237-51.
7. Dworkin RH, O'Connor AB, Audette J, Baron R, Gourlay GK, Haanpää ML, Kent JL, Krane EJ, Lebel AA, Levy RM, Mackey SC, Mayer J, Miaskowski C, Raja SN, Rice AS, Schmader KE, Stacey B, Stanos S, Treede RD, Turk DC, Walco GA, Wells CD. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc 2010;85:S3-S14.
8. European Medicines Agency. European Medicines Agency finalises review of antidepressants in children and adolescents. Available at: ; May 25, 2005 [Accessed 26.12.2013].
9. Evers S, Afra J, Frese A, Goadsby PJ, Linde M, May A, Sandor PS. EFNS guideline on the drug treatment of migraine: revised report of an EFNS task force. Eur J Neurol 2009;16:968-81.
10. Ferguson D, Doucette S, Glass KC, Shapiro S, Healy D, Hebert P, Hutton B. Association between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomised controlled trials. BMJ 2005;330:396.
11. Gibbons RD, Amatya AK, Brown CH, Hur K, Marcus SM, Bhaumik DK, Mann JJ. Post-approval drug safety surveillance. Annu Rev Public Health 2010;31:419-37.
12. Gibbons RD, Brown CH, Hur K, Marcus SM, Bhaumik DK, Mann JJ. Relationship between antidepressants and suicide attempts: an analysis of the Veterans Health Administration data sets. Am J Psychiatry 2007;164:1044-9.
13. Gibbons RD, Hur K, Brown CH, Davis JM, Mann JJ. Benefits from antidepressants: synthesis of 6-week patient-level outcomes from double-blind placebo-controlled randomized trials of fluoxetine and venlafaxine. Arch Gen Psychiatry 2012;69:572-9.
14. Gibbons RD, Segawa E, Kmatya AK, Bhaumik DK, Bhaumik DK, Brown CH, Kapur K, Marcus SM, Hur K, Mann JJ. Mixed-effects poisson regression analysis of adverse event reports: the relationship between antidepressants and suicide. Stat Med 2008;27:1814-33.
15. Gunnell D, Saperia J, Ashby D. Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta-analysis of drug company data from placebo-controlled, randomized controlled, randomized controlled trials submitted to the MHRA's safety review. BMJ 2005;330:385.
16. Hawton K, Bergen H, Simkin S, Cooper J, Waters K, Gunnell D, Kapur N. Toxicity of antidepressants: rates of suicide relative to prescribing and non-fatal overdose. Br J Psychiatry 2010;196:354-8.
17. Llgen MA, Zivin K, McCammon RJ, Valenstein M. Pain and suicidal thoughts, plans and attempts in the United States. Gen Hosp Psychiatry 2008;30:521-7.
18. Martinez C, Rietbrock S, Wise L, Ashby D, Chick J, Moseley J, Evans S, Gunnell D. Antidepressant treatment and the risk of fatal and non-fatal self harm in first episode depression: nested case-control study. BMJ 2005;330:389.
19. Meyer RE, Salzman C, Youngstrom EA, Clayton PJ, Goodwin FK, Mann JJ, Alphs LD, Broich K, Goodman WK, Greden JF, Meltzer HY, Normand SLT, Posner K, Shaffer D, Oquendo MA, Stanley B, Trivedi MH, Turecki G, Beasley Jr CM, Beautrais AL, Bridge JA, Brown GK, Revicki DA, Ryan ND, Sheehan DV. Suicidality and risk of suicide: definition, drug safety concerns, and a necessary target for drug development: a brief report. J Clin Psychiatry 2010;71:1040-6.
20. Meyer RE, Salzman C, Youngstrom EA, Clayton PJ, Goodwin FK, Mann JJ, Alphs LD, Broich K, Goodman WK, Greden JF, Meltzer HY, Normand SLT, Posner K, Shaffer D, Oquendo MA, Stanley B, Trivedi MH, Turecki G, Beasley Jr CM, Beautrais AL, Bridge JA, Brown GK, Revicki DA, Ryan ND, Sheehan DV. Suicidality and risk of suicide: definition, drug safety concerns, and a necessary target for drug development: a consensus statement. J Clin Psychiatry 2010;71:e1-e21.
21. Mulder RT, Joyce PR, Frampton CM, Luty SE. Antidepressant treatment is associated with a reduction in suicidal ideation and suicide attempts. Acta Psychiatr Scand 2008;118:116-22.
22. Olfson M, Marcus SC, Shaffer D. Antidepressant drug therapy and suicide in severely depressed children and adults: a case-control study. Arch Gen Psychiatry 2006;63:865-72.
23. ® 2013;154:345-9.
24. Posner K, Brown GK, Stanley B, Brent DA, Yershova KV, Oquendo MA, Currier GW, Melvin GA, Greenhill L, Shen S, Mann JJ. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry 2011;168:1266-77.
25. Posner K, Oquendo MA, Gould M, Stanley B, Davies M. Columbia Classification Algorithm of Suicide Assessment (C-CASA): classification of suicidal events in the FDA's pediatric suicidal risk analysis of antidepressants. Am J Psychiatry 2007;164:1035-43.
26. Racine M, Choinière M, Nielson WR. Predictors of suicidal ideation in chronic pain patients: an exploratory study. Clin J Pain 2014;30:371-8.
27. Ratcliffe GE, Enns MW, Belik SL, Sareen J. Chronic pain conditions and suicidal ideation and suicide attempts: an epidemiologic perspective. Clin J Pain 2008;24:204-10.
28. Rubino A, Roskell N, Tennis P, Mines D, Weich S, Andrews E. Risk of suicide during treatment with venlafaxine, citalopram, fluoxetine, and dothiepin: retrospective cohort study. BMJ 2007;334:242.
29. Schneeweiss S, Patrick AR, Solomon DH, Mehta J, Dormuth C, Miller M, Lee JC, Wang PS. Variation in the risk of suicide attempts and completed suicides by antidepressant agent in adults: a propensity score-adjusted analysis of 9 years' data. Arch Gen Psychiatry 2010;67:497-506.
30. Simon GE, Savarino J, Operskalski B, Wang PS. Suicide risk during antidepressant treatment. Am J Psychiatry 2006;163:41-7.
31. Sinyor M, Howlett A, Cheung AH, Schaffer A. Substances used in completed suicide by overdose in Toronto: an observational study of coroner's data. Can J Psychiatry 2012;57:184-91.
32. Stahl SM, Grady MM, Moret C, Briley M. SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. CNS Spectr 2005;10:732-47.
33. Stone M, Laughren T, Jones ML, Levenson M, Holland PC, Hughes A, Hammad TA, Temple R, Rochester G. Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration. BMJ 2009;339:b2880.
34. Tang NK, Crane C. Suicidality in chronic pain: a review of the prevalence, risk factors and psychological links. Psychol Med 2006;36:575-86.
35. U. S. Food and Drug Administration. Suicidality in children and adolescents being treated with antidepressant medications. Available at: ; October 15, 2004 [Accessed 26.12.2013].
36. U. S. Food and Drug Administration. Clinical review: relationship between antidepressant drugs and suicidality in adults. Available at: ; November 16, 2006 [Accessed 26.12.2013].
37. U. S. Food and Drug Administration. Antidepressant use in children, adolescents, and adults. Available at: ; May 2, 2007 [Accessed 27.12.2013].
38. U. S. Food and Drug Administration. FDA clears Cymbalta to treat chronic musculoskeletal pain. Available at: ; November 4, 2010 [Accessed 26.12.2013].
39. U. S. Food and Drug Administration. Guidance for industry: suicidal ideation and behavior: prospective assessment of occurrence in clinical trials. Available at: ; August, 2012 [Accessed 26.12.2013].
40. White N, Litovitz T, Clancy C. Suicidal antidepressant overdoses: a comparative analysis by antidepressant type. J Med Toxicol 2008;4:238-50.